Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction

Creative Commons License

Saylan M., Khalaf I., Kadioglu A., Shoair K. Z., Beheiry A., Wang W. C., ...More

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.60, no.7, pp.812-819, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 7
  • Publication Date: 2006
  • Doi Number: 10.1111/j.1742-1241.2006.00993.x
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.812-819
  • Keywords: tadalafil, erectile dysfunction, randomised controlled trial, QUALITY-OF-LIFE, DOUBLE-BLIND, SAFETY, SILDENAFIL, PHARMACOTHERAPY, PARALLEL, THERAPY
  • Dokuz Eylül University Affiliated: Yes


A randomised, double-blind, parallel, placebo-controlled, 12-week study was carried out to evaluate the efficacy and safety of 20-mg tadalafil taken 'as needed' in a population of men with erectile dysfunction (ED) from Egypt and Turkey. One hundred and thirty-two patients were randomised in this study. Tadalafil was superior to placebo on all three co-primary efficacy end points. The mean change from baseline for the erectile function domain of the International Index of Erectile Function was 9.3 +/- 0.8 for the tadalafil group and 2.3 +/- 1.6 for the placebo group. Tadalafil-treated patients reported a significantly greater improvement in the mean percentage of successful penetrations (tadalafil: 34.5 +/- 4.1; placebo: -4.6 +/- 8.1) and successful intercourse attempts (tadalafil: 52.2 +/- 3.8; placebo: 16.8 +/- 7.8) than placebo-treated patients as measured by the Sexual Encounter Profile. Tadalafil was generally well tolerated with 82% of adverse events being mild in severity. Tadalafil 20-mg taken 'as needed' significantly improved the erectile function in Egyptian and Turkish men with ED.